At 50 mcg, single oral dose (low end):

• Onset 60-90 min; peak 2-3 hr. Subtle. Many users feel nothing on the first dose, especially if choline-replete or first time.
• Mild mental clarity, slightly faster word recall, easier sustained focus on reading/writing tasks. Cleaner than caffeine — no peripheral activation.
• Duration: 6-10 hr of subjective effect; AChE inhibition persists ~6-8 hr.

At 100 mcg, single oral dose (mid-range):

• More consistent subjective effect. ~70% of users report something at 100 mcg single dose if not already chronic on cholinergics.
• Described as: "my brain feels sharper but quieter — like the noise is turned down and the signal is turned up." Word recall faster, mental fatigue resistance higher, sustained focus easier.
• Onset: 60-90 min reliably. Peak 2-4 hr. Soft tail extends 8-10 hr.
• Pre-bed dosing → vivid dreams, increased REM density, occasionally lucid dreams. Sleep continuity sometimes degraded.

At 200 mcg, single oral dose (top of nootropic range):

• Stronger, more reliable. ~80-90% of users report a felt effect.
• More likely to produce cholinergic side effects: mild nausea (especially on empty stomach), mild sweating, slight bradycardia, fasciculations (muscle twitches in face/eyelid), vivid dreams if daytime dose tail reaches sleep.
• This is the dose at which the NMDA antagonist component starts contributing (mild, sub-anesthetic, may add to "calmness" or "quieting" of mental noise).

At 400 mcg+ (Chinese Rx dose, 200 mcg BID):

• Clinical AD dose, not recommended for nootropic use in healthy young adults. At this dose:
• Cholinergic side effects become more common: nausea, sweating, GI hypermotility, vivid dreams, occasional muscle fasciculations. Some users report bradycardia (HR drop 5-10 bpm).
• Lucid dreaming community uses this dose pre-bed; not recommended chronic for any reason.
• At 400+ mcg the long half-life problem becomes severe — daily dosing at this level produces continuous AChE inhibition with steep tolerance curve (3-4 weeks) and pronounced rebound flatness on stopping.

Variability:

• ~70-80% of healthy users feel something at 100-200 mcg single dose. 20-30% feel nothing.
• Non-responders often already on alpha-GPC or citicoline at high dose (saturated cholinergic system) or have BChE polymorphisms that alter peripheral cholinergic exposure.
• Dylan-specific: he's already on citicoline 500 mg daily, which means his choline supply is already elevated. Adding huperzine on top should produce a larger signal than huperzine alone in a non-supplementing user — but also a higher cholinergic excess risk if he ramps too fast.

On stopping after 3-4 weeks daily:

• Some users report 1-2 weeks of mental flatness, mild dysphoria, sluggish word recall. This is the post-synaptic receptor recovery period. Resolves on its own. This is the rebound that cycling 4 on / 1-2 off is designed to prevent.

• Acute single-dose effect tolerance: moderate. Daily dosing produces measurable receptor downregulation within 2-3 weeks at 100-200 mcg/day. Subjective effect attenuates noticeably by week 3-4 in most users.
• Mechanism of tolerance: post-synaptic muscarinic M1/M3 + nicotinic α4β2/α7 receptor downregulation in response to chronic acetylcholine elevation. Also: choline depletion at the synapse if dietary/supplemental choline is insufficient (though Dylan's citicoline addresses this).
• Cycling: REQUIRED if dosing daily. 4 weeks on / 1-2 weeks off is the consensus protocol in the nootropics community and aligns with the receptor-recovery timeline. Some users use 6 on / 2 off.
• Reset protocol: 2-week complete washout. AChE recovery is fast (days); receptor density recovery is slower (1-2 weeks).
• Alternative for low-dose users: PRN 1-2× per week (max 50-100 mcg) skips the cycling problem entirely because steady-state never builds. This is the recommended pattern for Dylan.

Synergistic with

• citicoline (Dylan's V4): ✅ Mechanistically complementary — synthesis + clearance. Citicoline supplies choline for ACh synthesis; huperzine slows ACh breakdown. Stack produces larger, longer cholinergic signal than either alone. For Dylan: this is the actual stack rationale. But: dose conservatively (50-100 mcg huperzine, not 200+) because citicoline is already elevating choline supply — the synaptic ACh signal additivity is real and the cholinergic excess threshold is closer than with huperzine alone.
• alpha-gpc (PRN): ✅ Same logic as citicoline — synthesis substrate + clearance inhibition. Acute pre-task stack: alpha-GPC 300 mg + huperzine 50-100 mcg, 60-90 min pre-task. Caution: if Dylan is already on citicoline daily, stacking all three (citicoline + alpha-GPC + huperzine) is over-stacking the cholinergic axis. Pick two of three, not all three.
• alcar (V5 plan): ✅ ALCAR provides the acetyl group; choline (from citicoline/alpha-GPC) provides the choline; huperzine slows breakdown. Three-way stack is mechanistically tight — high cholinergic signal under cognitive load. Same caveat: dose conservatively.
• caffeine + l-theanine: ✅ Clean pre-task combo. Caffeine 100-200 mg + L-theanine 200 mg + huperzine 50-100 mcg, 60-90 min pre-task. Adenosine antagonism + α-wave + cholinergic = focus, drive, vigilance.
• modafinil (V5 plan): ✅ Modafinil increases cortical activation → higher acetylcholine demand. Huperzine slows breakdown, citicoline supplies substrate. Anecdotally smooths modafinil's cognitive ceiling. Stack-safe at moderate doses.
• bromantane (V5 plan): ✅ Bromantane drives dopaminergic tone; huperzine drives cholinergic tone. Dopaminergic + cholinergic axes balance each other in cortical attention networks. Stack-safe.
• DHA / phosphatidylserine (V4): ✅ Membrane substrates for healthy cholinergic signaling. Stack-safe and synergistic.

Avoid stacking with

• Donepezil, galantamine, rivastigmine (Rx AChE inhibitors): ❌ Cholinergic excess / crisis risk. Multiple AChE inhibitors stacked = additive AChE inhibition with no rate-limiting step. Severe nausea, bradycardia, hypotension, fasciculations possible. Not relevant for Dylan (no Rx AChEI) but absolute contraindication if he ever starts one.
• Other huperzine-containing nootropic stacks (Alpha BRAIN, Mind Lab Pro, etc.): ⚠️ Read labels — total daily huperzine across products is the relevant number. Don't stack a "huperzine stack" with standalone huperzine.
• Anticholinergic medications (diphenhydramine, oxybutynin, tricyclic antidepressants, scopolamine, atropine): ❌ Direct mechanistic antagonism — anticholinergic drugs block muscarinic receptors; huperzine raises ACh trying to activate the same receptors. Net effect: blunted huperzine effect AND blunted anticholinergic effect. Not dangerous, just mutually canceling. Diphenhydramine (Benadryl) and Unisom — don't combine with huperzine, won't work.
• Succinylcholine (surgical paralytic): ❌ Prolonged paralysis risk. Succinylcholine is metabolized by BChE; huperzine is highly AChE-selective (1000:1) so this is theoretical, but other less-selective AChE inhibitors definitively prolong succinylcholine paralysis. Tell anesthesiologist before any surgery.
• Beta-blockers (propranolol) at high dose: ⚠️ Additive bradycardia. Probably tolerable at moderate doses but watch HR.
• Calcium channel blockers (verapamil, diltiazem): ⚠️ Additive bradycardia / AV block risk. Watch HR + 1° AV block on ECG if used.
• Nicotine, varenicline: ⚠️ Cholinergic stacking. Huperzine + heavy nicotine = potentiated cholinergic activation. Not absolute contraindication, just additive.

Neutral / safe co-administration

• All current V4 stack items (NAC, magnesium glycinate/threonate, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, fish oil, creatine).
• All planned V5 additions except duplicate cholinergics handled above.
• Caffeine, L-tyrosine, ashwagandha — all neutral.

• Anticholinergics (antagonism): see above — direct mechanistic antagonism.
• Cholinergics (additive): see above — donepezil, galantamine, rivastigmine, pyridostigmine all stack additively. Avoid.
• Succinylcholine: theoretical prolongation of neuromuscular block. Anesthesiologist heads-up before surgery.
• Beta-blockers, calcium channel blockers: additive bradycardia. Monitor HR.
• Anticoagulants (warfarin, DOACs): no clinically significant interaction.
• CYP enzymes: Huperzine A is not a meaningful CYP inducer or inhibitor at therapeutic doses. Pharmacokinetic interactions essentially nil.
• Hormonal contraceptives: no interaction.
• Antiepileptics: mixed — cholinergic activation can lower seizure threshold (caution in epilepsy) but NMDA antagonist component is being studied as anti-epileptic. Not a clean answer.
• NSAIDs, paracetamol, common OTC analgesics: no interaction.

• BChE (butyrylcholinesterase) variants — BChE is the secondary plasma cholinesterase. Variants affect succinylcholine metabolism (the K-variant, atypical-A variant, silent variants). Huperzine A is highly AChE-selective (1000:1), so BChE variants matter less for huperzine itself, but BChE-deficient users (homozygous atypical) have higher overall cholinergic sensitivity and tolerate AChE inhibitors less well. Relevant for Dylan post-23andMe (June 2026) — if BChE variants flagged, dose conservatively.
• APOE ε4 — carriers show earlier cholinergic deficit in cognitive aging; AChE inhibitors may produce stronger cognitive benefit. If Dylan's 23andMe shows APOE ε4+, huperzine A moves toward STRONG-CANDIDATE for cognitive preservation alongside citicoline. ε4-positive carriers should treat huperzine + citicoline + DHA + PS as a coordinated cholinergic-membrane preservation stack.
• CHRNA4, CHRNA7, CHRM1, CHRM2 (cholinergic receptors): theoretical modulators of huperzine response. Limited clinical PGx data.
• CHAT (choline acetyltransferase): polymorphisms affect ACh synthesis efficiency upstream of huperzine's mechanism. Limited data.
• Pseudocholinesterase deficiency (BChE silent variants): rare; carriers have severely prolonged response to succinylcholine and may be more sensitive to AChE inhibitors generally. Worth flagging if ever scheduled for surgery.

Action for Dylan: When 23andMe results land (~June 5-15, 2026), check APOE ε4 (huperzine moves toward chronic-add candidacy if ε4+) and BChE variants (dose conservatively if any flagged).

Recommendation for Dylan: Nootropics Depot 100 mcg × 60 caps ($15-18, 60 doses) OR Source Naturals 200 mcg × 60 caps ($15) and split with pill cutter for 100 mcg dosing. Either gives ~6-12 months of PRN supply at 1-2×/week. Total cost: ~$2-5/month steady-state. Negligible vs V4/V5 budget.

Iherb already in supply chain → Source Naturals 100 mcg or 200 mcg (split) is cleanest match for Dylan's existing iHerb workflow.

Baseline (before starting)

• Resting HR + BP — establishes baseline before potential bradycardia
• Sleep tracking (Oura, Whoop, ring) — REM%, sleep efficiency, sleep onset latency. Huperzine shifts REM, want to know baseline.
• Subjective mood baseline — 1-10 daily mood + affect log for 1-2 weeks pre-start (anchor for detecting cholinergic dysphoria)
• Cognitive baseline — pick 2-3 standardized tests (Cambridge Brain Sciences, Quantified Mind, dual n-back) for objective tracking
• Optional: ECG if any conduction concern, asthma status, BChE genotype (post-23andMe)

During use

• HR (daily, ring/wearable): flag if resting HR drops >10 bpm sustained
• Sleep architecture (Oura): REM% should bump up acutely; if REM dominates >30% chronically, sleep architecture is shifted, consider reducing dose
• Mood/affect (weekly): weekly 1-10 mood + flat-affect screen during week 3-4 of any chronic use (the dysphoria window)
• GI tolerance, sweating, fasciculations: subjective notes

Post-cycle (if cycled)

• Mood + cognitive performance through 1-2 week washout: rebound flatness should resolve by end of week 2; if not, longer washout needed
• Sleep architecture should normalize within 3-7 days